Efficacy, tolerability and safety of long-term darifenacin treatment in older patients with overactive bladder: analysis of results from a 2-year, open-label extension study

Dwyer P1, Lheritier K2, Steel M2 1. Mercy Hospital for Women, Melbourne, Australia, 2. Novartis Pharma AG, Basel, Switzerland

Abstract